Teitur Trophics Receives Eurostars Funding to Support Pipeline Project in Hearing Loss

[RingerBell]

We are thrilled to announce that Teitur has received a Eurostars grant for the project Breakthrough Regenerative Peptide Therapy to Cure Patients with Sensorineural Hearing Loss (RE-HEAR). The RE-HEAR project is a collaboration between Teitur Trophics, the French biotech company CILcare and the School of Life Sciences at the University of Applied Sciences Northwestern Switzerland (FHNW) and aims to advance novel peptide-based therapeutics targeting hidden hearing loss and age-related hearing loss.

Teitur's proprietary peptides harness a unique targeted action on pathways of the SorCS2 receptor, potentially providing sustained therapeutic effects, beneficial to patients with sensorineural hearing loss. The €2M RE-HEAR project aims to progress peptides through preclinical proof of concept studies. This initiative encompasses research on delivery methods, as well as in vivo and in vitro efficacy evaluations using innovative hearing loss models created by CILcare and FHNW specifically for this project.

Re-HEAR will run over a 36-month period and is set to commence in April 2025. Stay tuned for more updates as we continue our journey towards making a meaningful impact in the hearing loss space!

Source: Teitur Trophics website

 

[Nick47]

This initiative encompasses research on delivery methods, as well as in vivo and in vitro efficacy evaluations using innovative hearing loss models created by CILcare and FHNW specifically for this project.

They will start with test tubes and then move on to small mammals. It will take at least three years before they can even begin discussions about designing a small human trial.